A Paradigm Shift in Snakebite Envenoming Therapy: From Conventional Antivenoms to Rationally Designed, Broadly Neutralizing Combination Therapies

Posted by
  A Paradigm Shift in Snakebite Envenoming Therapy: From Conventional Antivenoms to Rationally Designed, Broadly Neutralizing Combination Therapies Abstract For over a century, polyclonal antivenom has been the cornerstone of snakebite therapy, saving countless lives. However, the current production method, based on immunizing large animals, has inherent limitations in terms of safety, stability, and supply reliability, thereby creating a pressing need for alternative technologies. This review charts the rise of next-generation antivenoms built on recombinant antibody engineering. We systematically survey the strategies for discovering and developing these molecules, from humanized monoclonal antibodies and VHHs to computationally designed proteins. Our central thesis is that achieving broad-spectrum neutralization against complex venoms requires a shift from single-agent approaches to rationally designed, oligoclonal “cocktail” therapies (defined mixtures of a few select therapeut...

In vitro inhibition of snake venom toxins by varespladib, marimastat, nafamostat and dimercaprol

Posted by

 

By Holger Krisp - Own work, CC BY 3.0, https://commons.wikimedia.org/w/index.php?curid=17574465

In vitro inhibition of snake venom toxins by varespladib, marimastat, nafamostat and dimercaprol

Abstract

Snakebite envenoming causes more than 130,000 deaths and more than 400,000 disabilities per year and has been classified as a priority Neglected Tropical Disease by the World Health Organization (WHO). While antivenom therapy remains the mainstay of snakebite treatment, small molecule therapeutics (SMTs) have been proposed as potential adjuncts to antivenom, particularly as oral treatment in the prehospital setting. Several SMTs have demonstrated efficacy in preclinical models of snakebite envenoming, with varespladib, a secreted phospholipase A2 (sPLA2) inhibitor, being granted orphan drug status for its potential to treat snakebite. The present study investigated the potential of four SMTs (e.g., varespladib, marimastat, nafamostat and dimercaprol) to neutralise toxic components present in the venom of southern African snake species. In vitro experimentation found that varespladib potently inhibited snake venom phospholipase A2 (svPLA2) activity in Bitis arietans (IC50 = 0.221 μM) and B. gabonica (IC50 = 0.276 μM). Marimastat exhibited potent inhibition of snake venom metalloproteinase (svMP) in several snake species with IC50 values ranging from 0.0042–3.06 μM, while dimercaprol, a metal chelator, was a lower potency svMP inhibitor with IC50 values ranging from 5.01–79.8 μM. Nafamostat proved to be an inhibitor of snake venom serine protease (svSP) in B. arietans (IC50 = 3.72 μM), B. gabonica (IC50 = 3.80 μM) and Causus rhombeatus (IC50 = 0.261 μM). These data demonstrate that SMTs are effective inhibitors of the relevant enzymes in several snake species and support the proposal that SMTs could be developed for therapeutic intervention in snakebite envenoming.
Le Roux, A., Cloete, S. J., Petzer, J. P., & Petzer, A. (2025). In vitro inhibition of snake venom toxins by varespladib, marimastat, nafamostat and dimercaprol. Toxicon, 108626. https://doi.org/10.1016/j.toxicon.2025.108626